Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting MS
نویسندگان
چکیده
منابع مشابه
Cognitive impairment differs between primary progressive and relapsing-remitting MS.
OBJECTIVES To characterize the cognitive abilities of patients with primary progressive multiple sclerosis (PPMS) and relapsing-remitting multiple sclerosis (RRMS) compared with healthy controls (HCs) matched for age, sex, and education level while considering the different characteristics of PPMS and RRMS and to compare the cognitive patterns of these types of multiple sclerosis. METHODS For...
متن کاملDifferences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS.
OBJECTIVE To investigate the cognitive skills of patients with relapsing remitting multiple sclerosis (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS) relative to healthy control subjects and to assess whether there is heterogeneity in the type of cognitive disabilities demonstrated by patients with different MS phenotypes. METHODS RRMS patients (n = 108), SPMS patie...
متن کاملSerum neurofilament light chain in relapsing-remitting MS
MS is a chronic disease of the CNS, well recognized for its diverse clinical presentations and outcomes. Clinicians continue to struggle to predict shortor long-term prognosis of persons affected by MS, to predict response to the growing array of diseasemodifying treatments available, and to identify persons at risk of serious adverse events from those treatments. As such, valid, reliable, and ...
متن کاملNeurofilament light chain predicts disease activity in relapsing-remitting MS
Objective To investigate whether serum neurofilament light chain (NF-L) and chitinase 3-like 1 (CHI3L1) predict disease activity in relapsing-remitting MS (RRMS). Methods A cohort of 85 patients with RRMS were followed for 2 years (6 months without disease-modifying treatment and 18 months with interferon-beta 1a [IFNB-1a]). Expanded Disability Status Scale was scored at baseline and every 6 ...
متن کاملAlemtuzumab improves preexisting disability in active relapsing-remitting MS patients
OBJECTIVE To characterize effects of alemtuzumab treatment on measures of disability improvement in patients with relapsing-remitting multiple sclerosis (RRMS) with inadequate response (≥1 relapse) to prior therapy. METHODS Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II, a 2-year randomized, rater-blinded, active-controlled, head-to-head, phase 3 trial, compar...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Neurochemistry
سال: 2018
ISSN: 0022-3042
DOI: 10.1111/jnc.14452